These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11754041)

  • 1. Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model.
    Fetterly GJ; Tamburlin JM; Straubinger RM
    Biopharm Drug Dispos; 2001 Sep; 22(6):251-61. PubMed ID: 11754041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1035-48. PubMed ID: 18791717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
    Dhanikula RS; Dhanikula AB; Panchagnula R
    Pharmazie; 2008 Jun; 63(6):439-45. PubMed ID: 18604987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
    Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
    Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of paclitaxel-containing liposomes in rats.
    Fetterly GJ; Straubinger RM
    AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.
    Ait-Oudhia S; Straubinger RM; Mager DE
    Pharm Res; 2012 Oct; 29(10):2833-44. PubMed ID: 22588463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
    Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
    Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.
    Crosasso P; Ceruti M; Brusa P; Arpicco S; Dosio F; Cattel L
    J Control Release; 2000 Jan; 63(1-2):19-30. PubMed ID: 10640577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.
    Zhou R; Mazurchuk RV; Tamburlin JH; Harrold JM; Mager DE; Straubinger RM
    J Pharmacol Exp Ther; 2010 Feb; 332(2):479-88. PubMed ID: 19861574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
    Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized delivery of paclitaxel using elastic liposomes: formulation development and evaluation.
    Utreja P; Jain S; Tiwary AK
    Drug Deliv; 2011 Jul; 18(5):367-76. PubMed ID: 21428706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel.
    Ceruti M; Crosasso P; Brusa P; Arpicco S; Dosio F; Cattel L
    J Control Release; 2000 Jan; 63(1-2):141-53. PubMed ID: 10640588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
    Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.
    Plasswilm L; Cordes N; Fietkau R; Sauer R
    Strahlenther Onkol; 1998 Jan; 174(1):37-42. PubMed ID: 9463563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study on pharmacokinetics and tissue distribution of a novel microemulsion based on the paclitaxel/L-OH lipid complex and paclitaxel injection in cremophor].
    Ma YL; Ye J; Zhang PX; Xia XJ; Liu YL
    Yao Xue Xue Bao; 2013 Nov; 48(11):1698-704. PubMed ID: 24475708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation.
    Utreja P; Jain S; Yadav S; Khandhuja KL; Tiwary AK
    Curr Drug Saf; 2011 Nov; 6(5):329-38. PubMed ID: 22424541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL.
    Ellis AG; Webster LK
    Cancer Chemother Pharmacol; 1999; 43(1):13-8. PubMed ID: 9923536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.